|
|
News Breaks | | | | November 13, 2012 | | 08:04 EDT |  | MNKD | MannKind, Colby Pharmaceutical announce license agreement
Colby Pharmaceutical and MannKind Corporation announced a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s novel MKC1106 active immunotherapy programs, which are currently being developed for the treatment of melanoma, prostate, hematological disorders and other human cancers. Under the terms of the agreement, Colby will pay MannKind upfront and milestone payments linked to the development, approval and commercialization of products, with upfront and potential milestone payments of approximately $140M total. MannKind will also receive tiered royalties on sales of products. | |
|
News For MNKD From The Last 14 Days Check below for free stories on MNKD the last two weeks. |
|
|
| May 22, 2013 | | 16:00 EDT |  | MNKD | Options Update; May 22, 2013
 Subscribe for More Information | | | 11:50 EDT | | MNKD | High option volume stocks: ZTS AIRM GLDD GTXI MNKD
Subscribe for More Information | | | 11:46 EDT | | MNKD | MannKind volatility elevated on sharp rally to 28-month high
Subscribe for More Information | | | May 17, 2013 | | 10:25 EDT |  | MNKD | Summer Street says more optimistic on MannKind approval
Summer Street says it is more optimistic that the current trials of MannKind's inhalable insulin Afrezza could lead to FDA approval. The firm notes the product is completing two phase III trials and that it has been skeptical of approval in the past. Summer Street does not have an official rating on shares of MannKind, which are up 22c to $5.38 in early trading. | | | May 9, 2013 | | 16:02 EDT |  | MNKD | MannKind reports Q1 EPS (15c), consensus (15c)
Cash and cash equivalents were $28M at March 31. | |
|
|
|
|
|
|
